908 Devices to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

908 Devices Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters

908 Devices Reports Third Quarter 2024 Financial Results and Updates 2024 Revenue Outlook

908 Devices to Participate in Upcoming Investor Conferences

908 Devices to Report Third Quarter 2024 Financial Results on November 12, 2024

908 Devices to Participate in Craig-Hallum Bioprocessing Conference

908 Devices Reports Second Quarter 2024 Financial Results and Reiterates 2024 Revenue Outlook

908 Devices reports its second-quarter 2024 financial results, showcasing a 16% revenue growth, driven by handheld devices.

908 Devices to Participate in Canaccord Genuity 44th Annual Growth Conference

908 Devices will participate in the Canaccord Genuity 44th Annual Growth Conference, where management will discuss strategic initiatives and growth plans.

908 Devices to Report Second Quarter 2024 Financial Results on August 6, 2024

908 Devices will report its second-quarter 2024 financial results on August 6, 2024, before market open.

908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors

908 Devices announces the appointment of Michele M. Leonhart, former DEA Administrator, to its Board of Directors.

908 Devices Enhances XplorIR Portable Analyzer to Simultaneously Identify and Quantify Hazardous Gases and Vapors

908 Devices enhances the XplorIR with a new quantification package, enabling identification & quantification nearly 5,000 hazardous gases & vapors.

email

Subscribe to Our Communications